AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04236440
Drug: BAY2586116 (B2)
RxNorm normalized name: VITAMIN B2
DrugBank: Riboflavin (DB00140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 80 μg BAY2586116 (nasal spray)
Trial: NCT04236440
Drug: BAY2586116 (C)
RxNorm normalized name: Vitamin C
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 160 μg BAY2586116 (pharyngeal spray with direct endoscopic application via a nostril). It is the same procedure as described under part B3.
Trial: NCT00536458
Drug: MINI CHEP
RxNorm normalized name: oxymetazoline hydrochloride Nasal Solution [Iliadin Mini]
DrugBank: Oxymetazoline (DB00935)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: chemotherapy minichep 6 courses
Trial: NCT01804413
Drug: Pegvisomant
RxNorm normalized name: Pegvisomant
DrugBank: Pegvisomant (DB00082)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pegvisomant 1 mg/kg injection 3 days before the glucagon test.
Trial: NCT01076270
Drug: plerixafor
RxNorm normalized name: Plerixafor
DrugBank: Plerixafor (DB06809)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given SC
Trial: NCT02543801
Drug: Liposomal Bupivacaine
RxNorm normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Periarticular injection
Trial: NCT02543801
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Periarticular injection
Trial: NCT02543801
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Included as an element of the Liposomal bupivacaine intervention periarticular injection
Trial: NCT02543801
Drug: Clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Included as an element of both interventions as a standard of care periarticular injection
Trial: NCT03501381
Drug: Entinostat
RxNorm normalized name: entinostat
DrugBank: Entinostat (DB11841)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entinostat should be taken 1-2 hours prior to the HD IL-2 infusion. Dose reductions for entinostat should be followed. Entinostat will continue after high dose IL-2 every 2 weeks
Trial: NCT03501381
Drug: Interleukin-2
RxNorm normalized name: INTERLEUKIN-2
DrugBank: Human interleukin-2 (DB14865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the event of clinical benefit after a course of HD IL-2 (stable disease or tumor shrinkage) patients will receive a second treatment course of HD IL-2 therapy. Patients with evidence of tumor shrinkage after the 2nd HD IL-2 treatment course may receive a 3rd treatment course of HD IL-2.
Trial: NCT00923806
Drug: Aldesleukin
RxNorm normalized name: Aldesleukin
DrugBank: Aldesleukin (DB00041)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 720,000 IU/kg intravenous over 15 minutes every 8 hours for up to 5 days
Trial: NCT03002675
Drug: Bydureon
RxNorm normalized name: Bydureon
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: exenatide (Bydureon) 2mg s.c. 1x/wk
Trial: NCT02499159
Drug: Liposomal Bupivicaine
RxNorm normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 266 mg, 20 mL total, diluted at surgeon's discretion, delivered by 22 gauge needle.
Trial: NCT03296540
Drug: Prasugrel (Crushed tablets)
RxNorm normalized name: prasugrel Oral Tablet
DrugBank: Prasugrel (DB06209)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: loading dose of 6 crushed tablets 10mg Prasugrel
Trial: NCT00937352
Drug: Bapineuzumab
RxNorm normalized name: Bapineuzumab
DrugBank: Bapineuzumab (DB11715)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg, administered via IV (in the vein) infusion every 13 weeks for 4 years.~1.0 mg/kg, administered via IV (in the vein) infusion every 13 weeks for 4 years.
Trial: NCT03525821
Drug: Ketamine Hydrochloride
RxNorm normalized name: Ketamine Hydrochloride
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intranasal use of ketamine 1mg/kg with nitrous oxide
Trial: NCT03541668
Drug: Alteplase
RxNorm normalized name: Alteplase
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients receive rt-PA in a dose of 0.9mg per kilogram of body weight(maximum,90 mg),10 percent of which was given as a blous followed by delivery of the remaining 90 percent as a constant infusion over a period of 60 minutes.
Trial: NCT00819091
Drug: BI 1356
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5mg orally (po) tablet qd
Trial: NCT03296540
Drug: Prasugrel (Integral tablets)
RxNorm normalized name: prasugrel Oral Tablet
DrugBank: Prasugrel (DB06209)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: loading dose of 6 integral tablets of 10mg Prasugrel
Trial: NCT00682760
Drug: Korean Botulinum toxin type A (KbtxA) and Botox injection
RxNorm normalized name: botulinum toxin type A Injection [Botox]
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Each vial of Botox and KbtxA contained 100 U of BTX-A in a sterile vacuum-derived form without preservatives. Each vial of KbtxA was identical to the placebo (Botox) vial, and all vials were reconstituted with 2.0 mL of 0.9% sterile nonpreserved saline solution to a final dilution of 5 U /0.1 mL. The dose of BTX-A per injection site was 2.5 U to 5 U, and the location, number of injection sites. Using a 30-gauge needle, injections were angled away from the center of lid to reduce the risk of spread into the levator muscle. Injection sites include the upper medial and lateral eyelid margins, lower lateral lid margins, and above the eyebrow.
Trial: NCT01599793
Drug: cabozantinib
RxNorm normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT02217514
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02217514
Drug: BI 44370 low dose
RxNorm normalized name: BI 44370 TA
DrugBank: BI 44370 TA (DB16037)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02217514
Drug: BI 44370 medium dose
RxNorm normalized name: BI 44370 TA
DrugBank: BI 44370 TA (DB16037)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02217514
Drug: BI 44370 high dose
RxNorm normalized name: BI 44370 TA
DrugBank: BI 44370 TA (DB16037)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03977792
Drug: Docosanol Cream 10%
DrugBank: Docosanol (DB00632)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Comparator product topically applied to infected area, 5 times a day, until complete healing of the infection.
Trial: NCT00000266
Drug: Flupenthixol
RxNorm normalized name: flupenthixol
DrugBank: Flupentixol (DB00875)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02381470
Drug: Faropenem
RxNorm normalized name: Faropenem
DrugBank: Faropenem (DB12190)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Faropenem 600mg
Trial: NCT02381470
Drug: Amoxicillin/clavulanic acid
DrugBank: Clavulanic acid (DB00766)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin 500mg/ clavulanic acid 125mg
Trial: NCT02381470
Drug: Cefadroxil
RxNorm normalized name: Cefadroxil
DrugBank: Cefadroxil (DB01140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefadroxil 1g
Trial: NCT02381470
Drug: Rifampicin
RxNorm normalized name: Rifampicin
DrugBank: Rifampin (DB01045)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifampicin 10mg/kg
Trial: NCT02808351
Drug: Berberine
RxNorm normalized name: berberine
DrugBank: Berberine (DB04115)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02097394
Drug: Bifidobacteri
RxNorm normalized name: BIFIDOBACTERIA
DrugBank: Bifidobacterium longum infantis (DB14222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bifidobacteri (2 tablet, po, tid)
Trial: NCT02097394
Drug: Combizym + Bifidobacteri
RxNorm normalized name: BIFIDOBACTERIUM
DrugBank: Bifidobacterium spp. (DB18530)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combizym( 1 tablet, po, tid) + Bifidobacteri (2 tablet, po, tid)
Trial: NCT02369484
Drug: Afatinib
RxNorm normalized name: Afatinib
DrugBank: Afatinib (DB08916)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 40mg p.o./ day until documented progression or unacceptable toxicity
Trial: NCT00329264
Drug: Quetiapine fumarate
RxNorm normalized name: Quetiapine Fumarate
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00642850
Drug: methoxy polyethylene glycol-epoetin beta [Mircera]
DrugBank: Methoxy polyethylene glycol-epoetin beta (DB09107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 120, 200 or 360 micrograms iv monthly (starting dose)
Trial: NCT00162422
Drug: albuterol
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01162967
Drug: Benznidazole
RxNorm normalized name: benznidazole
DrugBank: Benznidazole (DB11989)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard dosage
Trial: NCT01162967
Drug: Posaconazole
RxNorm normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01673308
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide 10 mg orally on days 1 to 21 of a 28-day cycle for at least 4 cycles until intolerance or disease progression.
Trial: NCT00141453
Drug: olmesartan medoxomil
RxNorm normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets 10, 20, or 40 mg
Trial: NCT02252042
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75 mg/m\^2 IV on Day 1 of each 3- week cycle
Trial: NCT02818309
Drug: Lesogaberan
RxNorm normalized name: Lesogaberan
DrugBank: Lesogaberan (DB11920)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg bid
Trial: NCT00071799
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azacitidine was injected subcutaneously (SC) at an initial dose of 75mg/m\^2/day for 7 days. The 7-day dosing was repeated every 28 days with dose adjustment based on predefined hematology and renal laboratory results. Number of cycles: Azacitidine treatment was to be continued until the end of the study unless treatment was discontinued due to unacceptable toxicity, relapse after complete or partial response, transformation to AML or disease progression.
Trial: NCT02345174
Drug: 89Zr-GSK2849330
RxNorm normalized name: 89ZR-BEVACIZUMAB
DrugBank: Bevacizumab zirconium Zr-89 (DB14907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 89Zr-GSK2849330 solution for intravenous administration diluted with GSK2849330 Solution for Infusion (unlabelled GSK2849330) with a target radioactivity of 37MBq and a total antibody concentration of 0.4 mg/mL or 1.2 mg/mL.
Trial: NCT01432106
Drug: Aliskerin/Valsartan and Rampiril
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will start on low dose Ramipril 10 mg or Valturna 150/160 at visit 2, and up-titrate to target dose of Ramipril 20 mg or Valturna 300/320 at visit 3. At visit 5, the addition of Hydrochlorothiazide (HCTZ) or amlodipine will be allowed to achieve the SBP target of \< 140 mmHg. High dose will then be maintained throughout the remainder of the study. In case of symptoms of low blood pressures, the study medication may be decreased to the low dose.~(However, all non-study medication will be manipulated, initially.)
Trial: NCT03065816
Drug: Z0063
RxNorm normalized name: Zolpidem
DrugBank: Zolpidem (DB00425)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: chewable tablets Route of administration: oral
Trial: NCT03065816
Drug: Gaviscon
RxNorm normalized name: Gaviscon
DrugBank: Aluminum hydroxide (DB06723)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: chewable tablets Route of administration: oral
Trial: NCT02656017
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monitoring of tolerability and symptoms.
Trial: NCT01308541
Drug: arm 1
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bolus Dose: two bolus doses of 15.0 mg/kg (first dose) and 8.0 mg/kg (second dose), 40 minutes apart.~Continuous Infusion Dose: Total dose of 42.0 mg/kg administered over 3 hours at an infusion rate of 0.40 mg/kg/min for 1 hour, followed by 0.20 mg/kg/min for 1 hour, followed by 0.10 mg/kg/min for 1 hour.
Trial: NCT01308541
Drug: LUSEDRA
RxNorm normalized name: Lusedra
DrugBank: Fospropofol (DB06716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mode of administration: intravenous (IV).Continuous Infusion Dose: Total dose of 42.0 mg/kg administered over 3 hours at an infusion rate of 0.40 mg/kg/min for 1 hour, followed by 0.20 mg/kg/min for 1 hour, followed by 0.10 mg/kg/min for 1 hour.
Trial: NCT01308541
Drug: Propofol (arm 3)
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mode of administration: intravenous (IV). A loading dose administered at a constant infusion rate of 0.20 mg/kg/min (0.50 mL/kg/min) for 10 minutes, followed by a constant-rate 2-hour infusion at 0.10 mg/kg/min; total dose infused over 130 minutes is 14.0 mg/kg.
Trial: NCT01824056
Drug: 18F-FDG
RxNorm normalized name: 18F-FDG
DrugBank: Fludeoxyglucose (18F) (DB09502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: During this study, subjects will receive a single i.v. administration of approximately 10 mCi 18F-FP-(+)-DTBZ immediately prior to imaging.~The proposed dose for this study is based on our phase I study. At the proposed human dose of 10 mCi, the whole body effective dose (ED) will be approximately 680 mrem. The estimated human ED is expected to be comparable to or below the range of other approved brain imaging agents, such as 18F-FDG.
Trial: NCT00004243
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00004243
Drug: oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03200808
Drug: mixed methylene blue compound injection
RxNorm normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Every patient received intradermal mixed methylene blue compound injection twice.
Trial: NCT04335253
Drug: EOS884448
RxNorm normalized name: Immunoglobulin g1, anti-(human receptor tigit) (human monoclonal eos884448 .gamma.1-chain), disulfide with human monoclonal eos884448 .kappa.-chain, dimer
DrugBank: Belrestotug (DB19066)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple Ascending Dose
Trial: NCT00111813
Drug: vorinostat
RxNorm normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vorinostat capsules. Treatment in 21 day cycles (participants receive vorinostat for 14 days followed by a 7 day break).
Trial: NCT00111813
Drug: bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib injection. Given twice weekly for 2 weeks with a 1 week break. Treatment in 21 day cycles.
Trial: NCT00937131
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Concentrate for solution for infusion, Intravenous use, 375mg/m2, Maximum 8 weekly infusions
Trial: NCT02664558
Drug: ubenimex
RxNorm normalized name: Ubenimex
DrugBank: Ubenimex (DB03424)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00657748
Drug: Lithium Gluconate (drug) Glyceryl Triacetate GTA (drug)
DrugBank: (2-BROMOETHYL)(2-'FORMYL-4'-AMINOPHENYL) ACETATE (DB07955)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium 1.3 mEq/kg/day (three administrations a day)during the study GTA 500 mg/kg/day in four administrations a day during the study
Trial: NCT04454840
Drug: Riluzole
RxNorm normalized name: Riluzole
DrugBank: Riluzole (DB00740)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The basic treatment is Riluzole 25\~50mg twice daily
Trial: NCT00984152
Drug: TDF/FTC Once-Daily + Raltegravir 400 mg Orally Twice-Daily
DrugBank: Raltegravir (DB06817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: TDF/FTC Once-Daily + Raltegravir 400 mg Orally Twice-Daily
Trial: NCT00984152
Drug: TDF/FTC + Efavirenz (Atripla) Once-Daily
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TDF/FTC + Efavirenz (Atripla) Once-Daily
Trial: NCT01609673
Drug: Everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: On the day of conversion (day 1), 2 mg everolimus will be introduced in the morning and at night, as morning dose of CsA or Tac will be maintained and evening dose of CsA or Tac will be reduced by 50%.~In two days, 2 mg everolimus will be associated with 50% of CsA or Tac original dosage, both in the morning and evening. After that, everolimus dose will be adjusted to achieve a C0 target level of 6-10 ng/mL. Once target levels of everolimus are met, the CNI drug will be suspended.
Trial: NCT00051194
Drug: Combination IOP Lowering Therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03279146
Drug: Tenofovir exalidex (TXL)
RxNorm normalized name: Tenofovir
DrugBank: Tenofovir exalidex (DB14925)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral formulations
Trial: NCT04430036
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alkylating antineoplastic agent
Trial: NCT04430036
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Antimetabolite antineoplastic agent
Trial: NCT03399604
Drug: LIQ861 Inhaled Treprostinil
RxNorm normalized name: Treprostinil Inhalation Solution
DrugBank: Treprostinil (DB00374)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: LIQ861 bulk powder is generated from a treprostinil/excipient matrix from which particles of precise size and shape are created and filled into a hydroxypropyl methylcellulose (HPMC) capsule (size 3). LIQ861 capsules are provided in capsule strengths of 25 μg, 50 μg, 75 μg and 100 μg treprostinil.
Trial: NCT00143949
Drug: enalapril
RxNorm normalized name: Enalapril
DrugBank: Enalapril (DB00584)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01085695
Drug: rabeprazole
RxNorm normalized name: Rabeprazole
DrugBank: Rabeprazole (DB01129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg normal tablet
Trial: NCT01085695
Drug: rabeprazole
RxNorm normalized name: Rabeprazole
DrugBank: Rabeprazole (DB01129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Type 1 granule containing rabeprazole 10 mg
Trial: NCT01085695
Drug: rabeprazole
RxNorm normalized name: Rabeprazole
DrugBank: Rabeprazole (DB01129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Type 2 granule containing rabeprazole 10 mg
Trial: NCT01085695
Drug: rabeprazole
RxNorm normalized name: Rabeprazole
DrugBank: Rabeprazole (DB01129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Type 3 granule containing rabeprazole 10 mg
Trial: NCT01108068
Drug: Lithium
RxNorm normalized name: Lithium
DrugBank: Lithium citrate (DB14507)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: lithium will be given for 6 months to patients with OPPG, starting at a low dose of 2.5 mg/kg daily, gradually increasing until a lithium blood level of 0.3-0.6 ng/dl is achieved.
Trial: NCT03062605
Drug: Iodine (Betadine)
RxNorm normalized name: Iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00143949
Drug: losartan
RxNorm normalized name: Losartan
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03405714
Drug: Brivaracetam
RxNorm normalized name: Brivaracetam
DrugBank: Brivaracetam (DB05541)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: * Pharmaceutical form: Solution for iv injection~* Route of administration: intravenous use~* Concentration: 10 mg/ml
Trial: NCT00642824
Drug: bevacizumab [Avastin]
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 15mg/kg iv or 7.5mg/kg on day 1, and subsequently once every 3 weeks
Trial: NCT02401945
Drug: DE-120
RxNorm normalized name: Glucagon like peptide-1 Elastin like peptide-120 fusion protein
DrugBank: Froniglutide (DB16178)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02401945
Drug: Aflibercept
RxNorm normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT04371757
Drug: α1-adrenergic block
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ninety minutes before starting the experimental exercise protocol, participants will be offered a capsule containing an α-1 adrenoreceptor blocker (Drozazosin; 0.05 mg / kg-1 body weight) and will be instructed to lie down. All capsules will be handled by a specialized pharmacy.
Trial: NCT01579526
Drug: FP01
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: comparison of different dosages
Trial: NCT02337036
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: These Patients are treated with tacrolimus after the Liver Transplantation
Trial: NCT00301236
Drug: Dexmethylphenidate HCl extended-release capsules
RxNorm normalized name: dexmethylphenidate hydrochloride Extended Release Oral Tablet
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04588246
Drug: Memantine
RxNorm normalized name: Memantine
DrugBank: Memantine (DB01043)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT02755259
Drug: Acetazolamide
RxNorm normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04389931
Drug: Omega 3
RxNorm normalized name: omega 3,6
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two tablets containing 1g Omega 3. Procedure:Periodontal treatment Scaling and root planning